Immunotherapy in Advanced Lung Cancer Treatment

Despite the improvement in overall survival (OS) by platinum-based chemotherapy (NSCLC Meta-Analyses Collaborative Group, 2008), prognosis remains unsatisfactory for patients with advanced non-small cell lung cancer (NSCLC). We discuss in this chapter the new era of advanced lung cancer systemic therapy represented by immunotherapy. First of all I presented one of the modalities of immunological diagnostics based on new technology. The mechanism of action of the immunoagents is shortly described. In the in most part of the chapter, the main immunotherapeutic agents used in lung cancer immunotherapy are analyzed: vaccines, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors, and checkpoint inhibitors. In the end of the chapter, the combination between immunotherapeutic agents is discussed

B3-06: Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)

n/